# HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

> **NCT05348811** · PHASE2 · COMPLETED · sponsor: **Zhongda Hospital** · enrollment: 25 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** HAIC combined with donafenib and sintilimab

## Key facts

- **NCT ID:** NCT05348811
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-13
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05348811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05348811, "HAIC Combined With Donafenib and Sintilimab for Unresectable ICC". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05348811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*